Naohiro Takeshita

Assistant Professor

Jikei University School of Medicine

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Medical Imaging Medical Imaging professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Naohiro Takeshita is an Assistant Professor at Jikei University School of Medicine in Japan. His research primarily focuses on the management and treatment outcomes of squamous cell carcinoma, with recent publications addressing induction chemotherapy, imaging-detected extranodal extension, and the use of novel therapeutic agents such as lenvatinib. He has contributed significantly to the understanding of treatment pathways for head and neck cancers and differentiated thyroid cancer.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (2)

Koichiro Wasano

Associate professor

Tokai University School of Medicine

JAPAN

View details

Masato Nagaoka

asistant professor

Jikei University School of Medicine

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Naohiro Takeshita

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Successful Endoscopic Management of Nasal Septum Squamous Cell Carcinoma Following Induction Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab: A Case Report.

Treatment outcomes of squamous cell carcinoma of the external auditory canal and potential benefit of induction chemotherapy followed by chemoradiotherapy.

Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan.

Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapy.

Induction chemotherapy and concurrent chemoradiotherapy with cisplatin for T4 nasoethmoidal squamous cell carcinoma: The value of paclitaxel, carboplatin and cetuximab (PCE).

Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck.

Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer.

Induction chemotherapy with paclitaxel, carboplatin, and cetuximab (PCE) followed by chemoradiotherapy for unresectable locoregional recurrence after curative surgery in patients with squamous cell carcinoma of the head and neck.

Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck.

Collaborators (2)

Koichiro Wasano

Masato Nagaoka

Make your next move.